Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
| ▸ | ESRRA | P11474 | 1/20 | 0.52 |
| ▸ | MPC2 | O95563 | 2/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935582 | 0.90 | PPARG (0.74) | PPARGFFAR1PPARAESRRAMPC2 | |
| SCHEMBL6359266 | 0.90 | PPARG (0.73) | PPARGFFAR1PPARAESRRAMPC2 | |
| SCHEMBL6359264 | 0.90 | PPARG (0.73) | PPARGFFAR1PPARAESRRAMPC2 | |
| SCHEMBL5935596 | 0.83 | PPARG (0.56) | PPARGFFAR1PPARAESRRAMPC2 | |
| Rivoglitazone SCHEMBL5319250 | 0.76 | PPARG (1.00) | PPARGFFAR1PPARAESRRAMPC2 | |
| Rivoglitazone SCHEMBL143498 | 0.76 | PPARG (1.00) | PPARGFFAR1PPARAESRRAMPC2 | |
| SCHEMBL6896700 | 0.76 | PPARG (0.86) | PPARGFFAR1PPARAESRRAMPC2 | |
| Rivoglitazone SCHEMBL2906120 | 0.76 | PPARG (1.00) | PPARGFFAR1PPARAESRRAMPC2 | |
| Rivoglitazone SCHEMBL6064788 | 0.76 | PPARG (0.98) | PPARGFFAR1PPARAESRRAMPC2 | |
| Rivoglitazone SCHEMBL1592290 | 0.76 | PPARG (0.98) | PPARGFFAR1PPARAESRRAMPC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | PPARG 380/4885FFAR1 1277/4885PPARA 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.